21:41 , Jun 13, 2019 |  BC Innovations  |  Emerging Company Profile

Gracell: Speeding up CAR T cells

With a platform that could reduce the manufacturing time of autologous CAR T cells from two weeks to one day, Gracell is lining up a set of therapies it could produce with the method. Gracell...
21:08 , May 23, 2019 |  BC Innovations  |  Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

Obsidian is building a tool kit of engineered proteins whose expression can be finely tuned with FDA-approved small molecules, and its first application is in boosting the efficacy of cell therapies through a deal with...
23:20 , Dec 18, 2018 |  BC Extra  |  Company News

Management tracks: AbbVie, Semma, Ziopharm

AbbVie Inc. (NYSE:ABBV) unveiled a new executive leadership team. It includes EVP of R&D and CSO Michael Severino, who will become vice chairman and president and be responsible for R&D, HR, operations and the corporate...
15:56 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Ziopharm raises $50M in private placement

Immunotherapy company Ziopharm Oncology Inc. (NASDAQ:ZIOP) raised $50 million through the sale of 18.9 million units at $2.64 in a private placement on Nov. 12. Each unit comprises one share and a five-year warrant to...
22:35 , Oct 19, 2018 |  BC Extra  |  Company News

Management tracks: AbbVie, Adverum

AbbVie Inc. (NYSE:ABBV) said EVP and CFO William Chase will retire in mid-2019. Effective immediately, Chase becomes EVP of finance and administration until his retirement and VP and Controller Robert Michael will succeed Chase as...
23:10 , Oct 17, 2018 |  BC Extra  |  Company News

Management tracks: Ziopharm, Merck

Immunotherapy company Ziopharm Oncology Inc. (NASDAQ:ZIOP) said CMO and EVP of R&D Francois Lebel will step down, effective Oct. 26. Merck & Co. Inc. (NYSE:MRK) hired Jim Scholefield as chief information and digital officer. He...
17:58 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

FDA places hold on upcoming Phase I for point-of-care CAR Ts

FDA placed a clinical hold on an upcoming Phase I trial sponsored by Ziopharm Oncology Inc. (NASDAQ:ZIOP), which would be the first for its third-generation, point-of-care CAR T cells that require two days for manufacturing....
23:50 , Jun 18, 2018 |  BC Extra  |  Clinical News

Hold for upcoming point-of-care CAR T trial sinks Ziopharm shares

FDA placed a clinical hold on an upcoming Phase I trial sponsored by Ziopharm Oncology Inc. (NASDAQ:ZIOP), which would be the first for its third-generation, point-of-care CAR T cells that require two days for manufacturing....
02:17 , Jun 9, 2018 |  BioCentury  |  Finance

ASCO ascent

Kinase inhibitor company Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) and cancer assay developer Genomic Health Inc. (NASDAQ:GHDX) each hit all-time highs in the wake of data readouts at the American Society of Clinical Oncology meeting in Chicago....
20:38 , May 17, 2018 |  BC Innovations  |  Emerging Company Profile

Beyond B cells

PureTech Health plc subsidiary Vor Biopharma Inc. plans to combine CAR T therapies with hematopoietic stem cells modified to go unrecognized by CAR Ts. The approach could increase the types of immune cells that can...